[Rich66]

Fine-tuning Nanotech to Target Cancer

Programmable nanoparticles have shown promise in early cancer trials, and may finally fulfill the promise of nanomedicine.

• Thursday, May 3, 2012

LINK

Even at a lower-than-usual dose, multiple lung metastases shrank or even disappeared after one patient received only two-hour-long intravenous infusions of an experimental cancer drug. Another patient saw her cervical tumor reduce by nearly 60 percent after six months of treatment. Though the drug trial—by Bind Biosciences in Cambridge, Massachusetts—of an experimental nanotechnology-based technique was designed simply to show whether the technology is safe, the encouraging results revive hopes that nanomedicine could realize its elusive promise.

http://medicalxpress.com/news/2012-0...-clinical.html

“I was out of options, and I wasn’t happy to hear that,” said Sorensen, a resident of Mesa. “I’m 47 years old and I’m not ready to say goodbye just yet.”
Sorensen then learned of the BIND-014 clinical trial being conducted through Virginia G. Piper Cancer Center Clinical Trials, and quickly joined the study in August of 2011. Virginia G. Piper Cancer Center Clinical Trials is a partnership between Scottsdale Healthcare and TGen that treats cancer patients with promising new drugs.